- Sharp Services is investing $100 million across its global facility network to expand clinical, packaging, and sterile manufacturing capabilities.
- The investment includes new pre-filled syringe, vial labeling, autoinjector, and sterile manufacturing lines in the US and Europe, with operations coming online through 2025–2026.
Sharp Services, a provider of pharmaceutical packaging, clinical trial services, and sterile manufacturing, has announced a $100 million investment across its global facilities to meet rising market demand for established and new medicines. The company operates six GMP facilities in the US and three in Europe.
The investment will enhance injectable and packaging capacity, including pre-filled syringes and autoinjectors. Sharp’s Netherlands site will expand GMP production to accommodate new vial labeling and syringe assembly, expected to come online in 2026. In Belgium, the company is expanding warehouse space with additional cold-chain and ambient storage and adding a syringe blistering suite.
In the US, Sharp’s Allentown campus will install a new pre-filled syringe assembly, vial labeling and packaging lines, high-speed cartoners, mid-speed bottling and automated pouch filling lines for powder and oral solid dose (OSD) products. These enhancements will support both existing products and new client opportunities. Sharp’s Macungie facility will add two autoinjector and pen assembly, labeling, and packaging lines, complementing a recent $20 million investment.
Sharp’s Bethlehem, PA site, supporting clinical services from preclinical to commercial, is installing a 2–8°C production room, -15°C to -25°C walk-in freezers, two new capsule filling machines, and an additional blister line for OSD products, with operations expected by the end of 2025. In Lee, MA, the company has committed $28 million to expand sterile manufacturing capacity, including a fourth isolator-based sterile filling line with lyophilization.
“These multi-site investments at Sharp reflect our ongoing commitment to support the evolving needs of our pharma and biopharma clients in each of our core businesses. We are strengthening our service offerings across our entire network to provide more capacity, new capabilities and greater efficiency thereby reinforcing our role as a trusted and experienced partner to our clients as we help them bring important medicines to patients around the world.”
Kevin Orfan, President & CEO of Sharp
